# US 2019/0314429 A1 · Cancer Treatment and Diagnosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314429 A1
- Document ID: US20190314429A1
- Status: Published application
- Kind: A1
- Application number: 16/284,975
- Filed: 2019-02-25
- Published: 2019-10-17
- Earliest claimed: 2015-06-11
- Assignees: University of Miami
- Applicants: University of Miami
- Inventors: Glen N. Barber
- Web page: https://patentgrep.com/patent/US20190314429A1

## CPC

- A61K 35/763: Herpes virus
- A61P 35/00: Antineoplastic agents
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- C12N 2710/16632: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/16633: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/154: Methylation markers
- C12Q 2600/156: Polymorphic or mutational markers
- C12Q 2600/158: Expression markers
- G01N 2333/4706: stimulating, promoting or activating activity
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present disclosure provides, in general, a method for selecting a therapy for treating cancer in a human subject and subsequently treating cancer in a subject, which includes isolating a cancer cell from a human subject having cancer, determining the functional activity of STING or cGAS in the cell; and selecting a therapy for the cancer based on the functional activity of the STING or cGAS in the cell. Also provided, if the functional activity of STING and/or cGAS is determined to be defective in the cell, the therapy selected is one that is effective at killing STING-deficient and/or cGAS-deficient cancer cells, e.g., therapy including administering to the subject an oncolytic virus.

## Claims

### Claim 1

A method for treating cancer in a human subject, the method comprising the steps of:
isolating a sample from a human subject having cancer;
determining the functional activity of STING in the sample;
selecting a therapy for the cancer based on the functional activity of the STING in the sample; and
treating the subject with the selected therapy.

### Claim 2 (depends on 1)

The method of claim 1, wherein the functional activity of STING is determined to be defective in the cell, and the therapy selected is one that is effective at killing STING-deficient cancer cells.

### Claim 3 (depends on 1)

The method of claim 1, wherein the subject has failed at least one chemotherapy regimen.

### Claim 4 (depends on 3)

The method of claim 3, wherein the chemotherapy regimen comprises administering to the subject an agent which causes DNA mutations.

### Claim 5 (depends on 2)

The method of claim 2, wherein the selected therapy comprises administering to the subject an oncolytic virus.

### Claim 6 (depends on 5)

The method of claim 5, wherein the oncolytic virus is derived from herpes simplex virus, vaccinia virus or Varicella Zoster virus.

### Claim 7 (depends on 1)

The method of claim 1, wherein the step of determining the functional activity of STING in the sample comprises analyzing the amount of cGAS in the cell.

### Claim at position 8

8-9. (canceled)

### Claim 10 (depends on 1)

The method of claim 1, comprising
determining the functional activity of STING in a sample from the subject having the cancer; and
if the sample does not have defective STING activity, administering a cancer treatment to the subject that does not cause DNA mutation.

### Claim 11

A method for treating cancer in a human subject, the method comprising the steps of:
isolating a sample from a human subject having cancer;
determining the functional activity of cGAS in the sample;
selecting a therapy for the cancer based on the functional activity of the cGAS in the sample, and
administering the selected therapy to the subject.

### Claim 12

A method for treating cancer comprising
a) administering a viral oncolytic therapy to a subject,
b) determining the level of STING or cGAS in a sample from the subject, wherein a decrease in STING or cGAS activity is predictive of a positive outcome of oncolytic therapy, and
c) i) if levels of STING in the subject are low, continuing oncolytic therapy; or
ii) if STING or cGAS levels are normal or partially active, discontinuing viral oncolytic therapy and/or administering a second agent that can increase STING levels in the subject in order to improve the outcome of the viral oncolytic therapy.

### Claim 13 (depends on 12)

The method of claim 12, wherein the viral oncolytic therapy comprises herpesvirus, Varicella Zoster virus or vaccinia virus.

### Claim 14 (depends on 1)

The method of claim 1, wherein the cancer is selected from the group consisting of colorectal cancer, colitis-associated cancer and melanoma.

### Claim 15 (depends on 1)

The method of claim 1, wherein the sample is a body fluid, cell, tissue sample, biopsy, tissue print, skin, hair, a soluble fraction of a cell preparation, or media in which cells were grown.

### Claim 16 (depends on 15)

The method of claim 15, wherein the body fluid is blood, urine, plasma, saliva, or cerebrospinal fluid.

### Claim 17 (depends on 1)

The method of claim 1 wherein an immune response in the cancer that is lacking STING activity or cGAS activity is enhanced by administration of an oncolytic virus.

### Claim 18 (depends on 18)

The method of claim 18, wherein the immune response includes modulation of T cell activity, modulation of dendritic cell activity, or modulation of immune cytokines.

### Claim 19 (depends on 1)

The method of claim 1, wherein the therapy results in increased tumor cell death and/or retarded tumor growth.
